Did you factor in the increased sales reps that should have improved sales not dropped them. I'm still not on board with Eisai and their sales group. Don't forget, these reps sell other drugs not just B. Marketing is still anemic on DTC. I don't see Eisai as being all in. Takeda has already said they will commit 1000 reps to Contrave now that's all in.